Literature DB >> 10440905

A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease).

M L Katz1, H Shibuya, P C Liu, S Kaur, C L Gao, G S Johnson.   

Abstract

The human hereditary ceroid-lipofuscinoses are a group of autosomal recessively inherited diseases characterized by massive accumulations of autofluorescent lysosomal storage bodies in the cells of many tissues and by neuronal degeneration throughout the central nervous system. There are a number of clinically and genetically distinct forms of ceroid-lipofuscinosis, the most common of which is the juvenile type, also known as Batten disease and CLN3. To study the mechanisms that lead to pathology in CLN3 and to evaluate potential therapies, a mouse model has been generated by targeted disruption of the mouse ortholog of the CLN3 gene (Cln3). As in affected humans, mice homozygous for the disrupted Cln3 allele show accumulation of autofluorescent storage material in neurons and other cell types. The storage material consists of membrane-bounded intracellular inclusions with ultrastructural features typical of the ceroid-lipofuscinoses. The accumulation of this storage material validates the Cln3 knockout mice as a model for the human disorder. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10440905

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  22 in total

1.  [NCL in animal models].

Authors:  K Rüther
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

Review 2.  Cathepsin deficiency as a model for neuronal ceroid lipofuscinoses.

Authors:  John J Shacka; Kevin A Roth
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

3.  Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.

Authors:  P Gupta; A A Soyombo; A Atashband; K E Wisniewski; J M Shelton; J A Richardson; R E Hammer; S L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease.

Authors:  Erin R Burnight; Laura R Bohrer; Joseph C Giacalone; Darcey L Klaahsen; Heather T Daggett; Jade S East; Robert A Madumba; Kristan S Worthington; Robert F Mullins; Edwin M Stone; Budd A Tucker; Luke A Wiley
Journal:  CRISPR J       Date:  2018-02

5.  A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.

Authors:  David E Sleat; Jennifer A Wiseman; Mukarram El-Banna; Kwi-Hye Kim; Qinwen Mao; Sandy Price; Shannon L Macauley; Richard L Sidman; Michael M Shen; Qi Zhao; Marco A Passini; Beverly L Davidson; Gregory R Stewart; Peter Lobel
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

6.  Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner.

Authors:  Kristina Oresic; Britta Mueller; Domenico Tortorella
Journal:  Biosci Rep       Date:  2009-06       Impact factor: 3.840

7.  pdf1, a palmitoyl protein thioesterase 1 Ortholog in Schizosaccharomyces pombe: a yeast model of infantile Batten disease.

Authors:  Steve K Cho; Sandra L Hofmann
Journal:  Eukaryot Cell       Date:  2004-04

8.  Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.

Authors:  Chun-Hung Chan; Hannah M Mitchison; David A Pearce
Journal:  Hum Mol Genet       Date:  2008-08-04       Impact factor: 6.150

Review 9.  Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).

Authors:  Madhu M Ouseph; Mark E Kleinman; Qing Jun Wang
Journal:  Ann N Y Acad Sci       Date:  2016-01-08       Impact factor: 5.691

Review 10.  Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.

Authors:  Sara Bozorg; Denia Ramirez-Montealegre; Mina Chung; David A Pearce
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.